Photoaffinity scanning in the mapping of the peptide receptor interface of class II G protein - Coupled receptors

Journal of Peptide Science

Volumn 10, Issue 4, 2004, Pages 179-203

  Pham, V I ^a   Sexton, Patrick M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Class II G protein coupled receptor; G protein coupled receptor; Peptide ligand binding; Photoaffinity scanning

Indexed keywords

BENZOPHENONE; CALCITONIN DERIVATIVE; CALCITONIN RECEPTOR; CALCITONIN RECEPTOR LIKE RECEPTOR; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCAGON DERIVATIVE; GLUCAGON LIKE PEPTIDE; GLUCAGON RECEPTOR; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; N BENZOYLPHENYLALANINE DERIVATIVE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE[7-34]; SECRETIN DERIVATIVE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

BINDING SITE; COMPUTER MODEL; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; HORMONE RECEPTOR INTERACTION; LIGAND BINDING; PEPTIDE MAPPING; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; BENZOPHENONES; BINDING SITES; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; PHOTOAFFINITY LABELS; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 1942519211     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.541     Document Type: Review

References (178)

1. Kolakowski LF Jr. GCRDb: a G protein-coupled receptor database. Recept. Channels 1994; 2: 1-7.
2. Hoon MA, Adler E, Lindemeier J, Battey JF, Ryba NJ, Zuker CS. Putative mammalian taste receptors: a class of taste-specific GPCRs with distinct topographic selectivity. Cell 1999; 96: 541-551.
3. Birnbaumer L. G proteins in signal transduction. Annu. Rev. Pharmacol. Toxicol. 1990; 30: 675-705.
4. Shacham S, Topf M, Avisar N, Glaser F, Marantz Y, Bar-Haim S, Noiman S, Naor Z, Becker OM. Modeling the 3D structure of GPCRs from sequence. Med. Res. Rev. 2001; 21: 472-483.
5. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 2000; 21: 90-113.
6. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289: 739-745.
7. Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G protein-coupled receptors (GPCRs). Biochemistry 2001; 40: 7761-7772.
8. Van Neuren AS, Muller G, Klebe G, Moroder L. Molecular modelling studies on G protein-coupled receptors: from sequence to structure? J. Recept. Signal. Transduct. Res. 1999; 19: 341-353.
9. Iiri T, Farfel Z, Bourne HR. G-protein diseases furnish a model for the turn-on switch. Nature 1998; 394: 35-38.
10. Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC. Sequence alignment of the G protein-coupled receptor superfamily. DNA Cell Biol. 1992; 11: 1-20.
11. Foord SM, Jupe S, Holbrook J. Bioinformatics and type II G protein-coupled receptors. Biochem. Soc. Trans. 2002; 30: 473-479.
12. Ulrich CD, Holtmann M, Miller LJ. Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. Gastroenterology 1998; 114: 382-397.
13. Vilardaga JP, Di Paolo E, Bialek C, De Neef P, Waelbroeck M, Bollen A, Robberecht P. Mutational analysis of extracellular cysteine residues of rat secretin receptor shows that disulfide bridges are essential for receptor function. Eur. J. Biochem. 1997; 246: 173-180.
14. Ho HH, Gilbert MT, Nussenzveig DR, Gershengorn MC. Glycosylation is important for binding to human calcitonin receptors. Biochemistry 1999; 38: 1866-1872.
15. Knudsen SM, Tams JW, Wulff BS, Fahrenkrug J. A disulfide bond between conserved cysteines in the extracellular loops of the human VIP receptor is required for binding activation. FEBS Lett. 1997; 412: 141-143.
16. Vilardaga JP, Lin I, Nissenson RA. Analysis of parathyroid hormone (PTH)/secretin receptor chimeras differentiates the role of functional domains in the PTH/PTH-related peptide (PTHrP) receptor on hormone binding and receptor activation. Mol. Endocrinol. 2001; 15: 1186-1199.
17. Stroop SD, Keustner RE, Serwold TF, Chen L, Moore EE. Chimeric human calcitonin and glucagon receptors reveal two dissociable calcitonin interaction sites. Biochemistry 1995; 34: 1050-1057.
18. Holtmann MH, Hadac EM, Miller LJ. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. J. Biol. Chem. 1995; 270: 14 394-14 398.
19. Stroop SD, Nakamuta H, Kuestner RE, Moore EE, Epand RM. Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions. Endocrinology 1996; 137: 4752-4756.
20. Perrin MH, Fischer WH, Kunitake KS, Craig AG, Koerber SC, Cervini LA, Rivier JE, Groppe JC, Greenwald J, Nielsen SM, Vale WW. Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor. J. Biol. Chem. 2001; 276: 31 528-31 534.
21. Perrin MH, DiGruccio MR, Koerber SC, Rivier JE, Kunitake KS, Bain DL, Fischer WH, Vale WW. A soluble form of the first extracellular domain of mouse type 2β corticotropin-releasing factor receptor reveals differential ligand specificity. J. Biol. Chem. 2003; 278: 15 595-15 600.
22. Grauschopf U, Lilie H, Honold K, Wozny M, Reusch D, Esswein A, Schafer W, Rucknagel KP, Rudolph R. The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. Biochemistry 2000; 39: 8878-8887.
23. 198 rather than negative charge. FEBS Lett. 2002; 530: 244-248.
24. Lopez de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D. The isolated N-terminal domain of the glucagon-like peptide 1 (GLP1) receptor binds exendin peptides with much higher affinity than GLP1. J. Biol. Chem. 2003; 278: 10 195-10 200.
25. Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P, Laburthe M. Highly conserved aspartate 68, tryptophan 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. Biochem. Biophys. Res. Commun. 1995; 206: 246-252.
26. Buggy JJ, Livingston JN, Rabin DU, Yoo-Warren H. Glucagon/glucagon-like peptide 1 receptor chimeras reveal domains that determine specificity of glucagon binding. J. Biol. Chem. 1995; 270: 7474-7478.
27. Holtmann MH, Ganguli S, Hadac EM, Dolu V, Miller LJ. Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J. Biol. Chem. 1996; 271: 14 944-14 949.
28. Unson CG, Cypess AM, Wu CR, Goldsmith PK, Merrifield RB, Sakmar TP. Antibodies against specific extracellular epitopes of the glucagon receptor block glucagon binding. Proc. Natl Acad. Sci. USA 1996; 93: 310-315.
29. Wilmen A, Van Eyll B, Goke B, Goke R. Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP1 receptor are essential for its ability to bind GLP1. Peptides 1997; 18: 301-305.
30. Hashimoto H, Ogawa N, Hagihara N, Yamamoto K, Imanishi K, Nogi H, Nishino A, Fujita T, Matsuda T, Nagata S, Baba A. Vasoactive intestinal polypeptide and pituitary adenylate cyclase- activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol. Pharmacol. 1997; 52: 128-135.
31. Dautzenberg FM, Wille S, Lohmann R, Spiess J. Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand- binding site. Proc. Natl Acad. Sci. USA 1998; 95: 4941-4946.
32. Clark JA, Bonner TI, Kim AS, Usdin TB. Multiple regions of ligand discrimination revealed by analysis of chimeric parathyroid hormone 2 (PTH2) and PTH/PTH-related peptide (PTHrP) receptors. Mol. Endocrinol. 1998; 12: 193-206.
33. Mannstadt M, Luck MD, Gardella TJ, Juppner H. Evidence for a ligand interaction site at the amino-terminus of the parathyroid hormone (PTH)/PTH-related protein receptor from cross-linking and mutational studies. J. Biol. Chem. 1998; 273: 16 890-16 896.
34. Adams AE, Bisello A, Chorev M, Rosenblatt M, Suva LJ. Arginine 186 in the extracellular N-terminal region of the human parathyroid hormone 1 receptor is essential for contact with position 13 of the hormone. Mol. Endocrinol. 1998; 12: 1673-1683.
35. Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P, Laburthe M. Vasoactive intestinal peptide (VIP) 1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J. Biol. Chem. 1996; 271: 12 795-12 800.
36. Bergwitz C, Jusseaume SA, Luck MD, Juppner H, Gardella TJ. Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH) 2 receptor determine signaling selectivity for PTH and PTH-related peptide. J. Biol. Chem. 1997; 272: 28 861-28 868.
37. Bisello A, Adams AE, Mierke DF, Pellegrini M, Rosenblatt M, Suva LJ, Chorev M. Parathyroid hormone-receptor interactions identified directly by photocross-linking and molecular modeling studies. J. Biol. Chem. 1998; 273: 22 498-22 505.
38. Gardella TJ, Luck MD, Fan MH, Lee C. Transmembrane residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signaling by agonist ligands. J. Biol. Chem. 1996; 271: 12 820-12 825.
39. Vilardaga JP, Frank M, Krasel C, Dees C, Nissenson RA, Lohse MJ. Differential conformational requirements for activation of G proteins and the regulatory proteins arrestin and G protein-coupled receptor kinase in the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein. J. Biol. Chem. 2001; 276: 33 435-33 443.
40. Bergwitz C, Gardella TJ, Flannery MR, Potts JT Jr, Kronenberg HM, Goldring SR, Juppner H. Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. Evidence for a common pattern of ligand-receptor interaction. J. Biol. Chem. 1996; 271: 26 469-26 472.
41. Feyen JH, Cardinaux F, Gamse R, Bruns C, Azria M, Trechsel U. N-terminal truncation of salmon calcitonin leads to calcitonin antagonists. Structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivo. Biochem. Biophys. Res. Commun. 1992; 187: 8-13.
42. Gelling RW, Coy DH, Pederson RA, Wheeler MB, Hinke S, Kwan T, McIntosh CH. GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP(1-42) action in vitro. Regul. Pept. 1997; 69: 151-154.
43. Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, Orskov C, Holst JJ, Poulsen SS. The truncated metabolite GLP2(3-33) interacts with the GLP2 receptor as a partial agonist. Regul. Pept. 2002; 103: 9-15.
44. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993; 42: 1678-1682.
45. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 1993; 268: 19 650-19 655.
46. Hoare SR, Usdin TB. Tuberoinfundibular peptide (7-39) [TIP(7-39)], a novel, selective, high-affinity antagonist for the parathyroid hormone-1 receptor with no detectable agonist activity. J. Pharmacol. Exp. Ther. 2000; 295: 761-770.
47. Hoare SR, Usdin TB. Specificity and stability of a new PTH1 receptor antagonist, mouse TIP(7-39). Peptides 2002; 23: 989-998.
48. Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 1997; 18: 1555-1560.
49. Turner JT, Jones SB, Bylund DB. A fragment of vasoactive intestinal peptide, VIP(10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29. Peptides 1986; 7: 849-854.
50. Smith DD, Saha S, Fang G, Schaffert C, Waugh DJ, Zeng W, Toth G, Hulce M, Abel PW. Modifications to the N-terminus but not the C-terminus of calcitonin gene-related peptide(8-37) produce antagonists with increased affinity. J. Med. Chem. 2003; 46: 2427-2435.
51. Williams KP, Shoelson SE. A photoaffinity scan maps regions of the p85 SH2 domain involved in phosphoprotein binding. J. Biol. Chem. 1993; 268: 5361-5364.
52. Dorman G, Prestwich GD. Benzophenone photophores in biochemistry. Biochemistry 1994; 33: 5661-5673.
53. Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP, Miller LJ. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. J. Biol. Chem. 1997; 272: 24 393-24 401.
54. Kojro E, Eich P, Gimpl G, Fahrenholz F. Direct identification of an extracellular agonist binding site in the renal V2 vasopressin receptor. Biochemistry 1993; 32: 13 537-13 544.
55. Blanton MP, Li YM, Stimson ER, Maggio JE, Cohen JB. Agonist-induced photoincorporation of a p-benzoylphenylalanine derivative of substance P into membrane-spanning region 2 of the Torpedo nicotinic acetylcholine receptor delta subunit. Mol. Pharmacol. 1994; 46: 1048-1055.
56. Keutmann HT, Rubin DA. A subunit interaction site in human luteinizing hormone: identification by photoaffinity cross-linking. Endocrinology 1993; 132: 1305-1312.
57. Li YM, Marnerakis M, Stimson ER, Maggio JE. Mapping peptide-binding domains of the substance P (NK-1) receptor from P388D1 cells with photolabile agonists. J. Biol. Chem. 1995; 270: 1213-1220.
58. Kage R, Leeman SE, Krause JE, Costello CE, Boyd ND. Identification of methionine as the site of covalent attachment of a p- benzoyl-phenylalanine-containing analogue of substance P on the substance P (NK-1) receptor. J. Biol. Chem. 1996; 271: 25 797-25 800.
59. Boyd ND, Kage R, Dumas JJ, Krause JE, Leeman SE. The peptide binding site of the substance P (NK-1) receptor localized by a photoreactive analogue of substance P: presence of a disulfide bond. Proc. Natl Acad. Sci. USA, 1996; 93: 433-437.
60. Girault S, Sagan S, Bolbach G, Lavielle S, Chassaing G. The use of photolabelled peptides to localize the substance-P-binding site in the human neurokinin-1 tachykinin receptor. Eur. J. Biochem. 1996; 240: 215-222.
61. McNicoll N, Gagnon J, Rondeau JJ, Ong H, De Lean A. Localization by photoaffinity labeling of natriuretic peptide receptor-A binding domain. Biochemistry 1996; 35: 12 950-12 956.
62. Adams AE, Pines M, Nakamoto C, Behar V, Yang QM, Bessalle R, Chorev M, Rosenblatt M, Levine MA, Suva LJ. Probing the bimolecular interactions of parathyroid hormone and the human parathyroid hormone/parathyroid hormone-related protein receptor. 2. Cloning, characterization, and photoaffinity labeling of the recombinant human receptor. Biochemistry 1995; 34: 10 553-10 559.
63. Zhou AT, Bessalle R, Bisello A, Nakamoto C, Rosenblatt M, Suva LJ, Chorev M. Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking. Proc. Natl Acad. Sci. USA 1997; 94: 3644-3649.
64. Carter PH, Shimizu M, Luck MD, Gardella TJ. The hydrophobic residues phenylalanine 184 and leucine 187 in the type-1 parathyrold hormone (PTH) receptor functionally interact with the amino-terminal portion of PTH(1-34). J. Biol. Chem. 1999; 274: 31 955-31 960.
65. Behar V, Bisello A, Bitan G, Rosenblatt M, Chorev M. Photoaffinity cross-linking identifies differences in the interactions of an agonist and an antagonist with the parathyroid hormone/parathyroid hormone-related protein receptor. J. Biol. Chem. 2000; 275: 9-17.
66. Greenberg Z, Bisello A, Mierke DF, Rosenblatt M, Chorev M. Mapping the bimolecular interface of the parathyroid hormone (PTH)-PTH1 receptor complex: spatial proximity between Lys(27) (of the hormone principal binding domain) and leu(261) (of the first extracellular loop) of the human PTH1 receptor. Biochemistry 2000; 39: 8142-8152.
67. Gensure RC, Gardella TJ, Juppner H. Multiple sites of contact between the carboxyl-terminal binding domain of PTHrP(1-36) analogs and the amino-terminal extracellular domain of the PTH/PTHrP receptor identified by photoaffinity cross-linking. J. Biol. Chem. 2001; 276: 28 650-28 658.
68. Gensure RC, Carter PH, Petroni BD, Juppner H, Gardella TJ. Identification of determinants of inverse agonism in a constitutively active parathyroid hormone/parathyroid hormone-related peptide receptor by photoaffinity cross-linking and mutational analysis. J. Biol. Chem. 2001; 276: 42 692-42 699.
69. Dong M, Wang Y, Pinon DI, Hadac EM, Miller LJ. Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the amino-terminal tail of the secretin receptor using photoaffinity labeling. J. Biol. Chem. 1999; 274: 903-909.
70. Dong M, Wang Y, Hadac EM, Pinon DI, Holicky E, Miller LJ. Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor. J. Biol. Chem. 1999; 274: 19 161-19 167.
71. Dong M, Asmann YW, Zang M, Pinon DI, Miller LJ. Identification of two pairs of spatially approximated residues within the carboxyl terminus of secretin and its receptor. J. Biol. Chem. 2000; 275: 26 032-26 039.
72. Behar V, Bisello A, Rosenblatt M, Chorev M. Direct identification of two contact sites for parathyroid hormone (PTH) in the novel PTH2 receptor using photoaffinity cross-linking. Endocrinology 1999; 140: 4251-4261.
73. Zang M, Dong M, Pinon DI, Ding XQ, Hadac EM, Li Z, Lybrand TP, Miller LJ. Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor. Mol. Pharmacol. 2003; 63: 993-1001.
74. Gaylinn BD. Growth hormone releasing hormone receptor. Recept. Channels 2002; 8: 155-162.
75. Lee C, Gardella TJ, Abou-Samra AB, Nussbaum SR, Segre GV, Potts JT Jr, Kronenberg HM, Juppner H. Role of the extracellular regions of the parathyroid hormone (PTH)/PTH-related peptide receptor in hormone binding. Endocrinology 1994; 135: 1488-1495.
76. Dong M, Zang M, Pinon DI, Li Z, Lybrand TP, Miller LJ. Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus. Mol. Endocrinol. 2002; 16: 2490-2501.
77. Clore GM, Nilges M, Brunger A, Gronenborn AM. Determination of the backbone conformation of secretin by restrained molecular dynamics on the basis of interproton distance data. Eur. J. Biochem. 1988; 171: 479-484.
78. Gronenborn AM, Bovermann G, Clore GM. A 1H-NMR study of the solution conformation of secretin. Resonance assignment and secondary structure. FEBS Lett. 1987; 215: 88-94.
79. Tan YV, Couvineau A, Van Rampelbergh J, Laburthe M. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor. J. Biol. Chem. 2003; 278: 36 531-36 536 (June 13th).
80. Lins L, Couvineau A, Rouyer-Fessard C, Nicole P, Maoret JJ, Benhamed M, Brasseur R, Thomas A, Laburthe M. The human VPAC1 receptor: three-dimensional model and mutagenesis of the N-terminal domain. J. Biol. Chem. 2001; 276: 10 153-10 160.
81. Olde B, Sabirsh A, Owman C. Molecular mapping of epitopes involved in ligand activation of the human receptor for the neuropeptide, VIP, based on hybrids with the human secretin receptor. J. Mol. Neurosci. 1998; 11: 127-134.
82. Houssami S, Findlay DM, Brady CL, Myers DE, Martin TJ, Sexton PM. Isoforms of the rat calcitonin receptor: consequences for ligand binding and signal transduction. Endocrinology 1994; 135: 183-190.
83. Juppner H. Molecular cloning and characterization of a parathyroid hormone/parathyroid hormone-related peptide receptor: a member of an ancient family of G protein-coupled receptors. Curr. Opin. Nephrol. Hypertens. 1994; 3: 371-378.
84. Lee CW, Luck MD, Juppner H, Potts JT, Jr K, H. M., Gardella TJ. Homolog-scanning mutagenesis of the parathyroid hormone (PTH) receptor reveals PTH-(1-34) binding determinants in the third extracellular loop. Mol. Endocrinol. 1995; 9: 1269-1278.
85. Gardella TJ, Juppner H. Interaction of PTH and PTHrP with their receptors. Rev. Endocr. Metab. Disord. 2000; 1: 317-329.
86. Bisello A, Behar V, Greenberg Z, Suva LJ, Rosenblatt M, Chorev M. Development of a photoreactive parathyroid hormone antagonist to probe antagonist-receptor bimolecular interaction. J. Pept. Res. 1999; 54: 120-128.
87. 2]PTH(1-34) binding and signaling in the transmembrane region of the parathyroid hormone receptor. Endocrinology 1994; 135: 1186-1194.
88. Carter PH, Petroni BD, Gensure RC, Schipani E, Potts JT Jr, Gardella TJ. Selective and nonselective inverse agonists for constitutively active type-1 parathyroid hormone receptors: evidence for altered receptor conformations. Endocrinology 2001; 142: 1534-1545.
89. Pellegrini M, Bisello A, Rosenblatt M, Chorev M, Mierke DF. Binding domain of human parathyroid hormone receptor: from conformation to function. Biochemistry 1998; 37: 12 737-12 743.
90. Jin L, Briggs SL, Chandrasekhar S, Chirgadze NY, Clawson DK, Schevitz RW, Smiley DL, Tashjian AH, Zhang F. Crystal structure of human parathyroid hormone 1-34 at 0.9-Å resolution. J. Biol. Chem. 2000; 275: 27 238-27 244.
91. Piserchio A, Bisello A, Rosenblatt M, Chorev M, Mierke DF. Characterization of parathyroid hormone/receptor interactions: structure of the first extracellular loop. Biochemistry 2000; 39: 8153-8160.
92. Riek RP, Rigoutsos I, Novotny J, Graham RM. Non-alpha-helical elements modulate polytopic membrane protein architecture. J. Mol. Biol. 2001; 306: 349-362.
93. Sexton PM, Findlay DM, Martin TJ. Calcitonin. Curr. Med. Chem. 1999; 6: 1067-1093.
94. Sexton PM. Recent advances in our understanding of peptide hormone receptors and RAMPS. Curr. Opin. Drug Discov. Dev. 1999; 2: 440-448.
95. Hilton JM, Dowton M, Houssami S, Sexton PM. Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. J. Endocrinol. 2000; 166: 213-226.
96. Hoare SR, Usdin TB. Molecular mechanisms of ligand recognition by parathyroid hormone 1 (PTH1) and PTH2 receptors. Curr. Pharm. Des. 2001; 7: 689-713.
97. Hoare SR, Gardella TJ, Usdin TB. Evaluating the signal transduction mechanism of the parathyroid hormone 1 receptor. Effect of receptor-G-protein interaction on the ligand binding mechanism and receptor conformation. J. Biol. Chem. 2001; 276: 7741-7753.
98. Usdin TB, Bonner TI, Hoare Sr. The parathyroid hormone 2 (PTH2) receptor. Recept. Channels 2002; 8: 211-218.
99. Chorev M. Parathyroid hormone 1 receptor: insights into structure and function. Recept. Channels 2002; 8: 219-242.
100. Rolz C, Pellegrini M, Mierke DF. Molecular characterization of the receptor-ligand complex for parathyroid hormone. Biochemistry 1999; 38: 6397-6405.
101. Gardella TJ, Luck MD, Wilson AK, Keutmann HT, Nussbaum SR, Potts JT Jr, Kronenberg HM. Parathyroid hormone (PTH)-PTH-related peptide hybrid peptides reveal functional interactions between the 1-14 and 15-34 domains of the ligand. J. Biol. Chem. 1995; 270: 6584-6588.
102. Elling CE, Nielsen SM, Schwartz TW. Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor. Nature 1995; 374: 74-77.
103. Elling CE, Schwartz TW. Connectivity and orientation of the seven helical bundle in the tachykinin NK-1 receptor probed by zinc site engineering. EMBO J 1996; 15: 6213-6219.
104. Laburthe M, Couvineau A, Marie JC. VPAC receptors for VIP and PACAP. Recept. Channels 2002; 8: 137-153.
105. 2. Endocrinology 1988; 123: 2597-2599.
106. McKee RL, Goldman ME, Caulfield MP, DeHaven PA, Levy JJ, Nutt RF, Rosenblatt M. The 7-34-fragment of human hypercalcemia factor is a partial agonist/antagonist for parathyroid hormone-stimulated cAMP production. Endocrinology 1988; 122: 3008-3010.
107. Dong M, Miller LJ. Molecular pharmacology of the secretin receptor. Recept. Channels 2002; 8: 189-200.
108. Purdue BW, Tilakaratne N, Sexton PM. Molecular pharmacology of the calcitonin receptor. Recept. Channels 2002; 8: 243-255.
109. Born W, Fischer JA, Muff R. Receptors for calcitonin gene-related peptide, adrenomedullin, and amylin: the contributions of novel receptor-activity-modifying proteins. Recept. Channels 2002; 8: 201-209.
110. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International Union of Pharmacology XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 2002; 54: 233-246.
111. Laburthe M, Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regul. Pept. 2002; 108: 165-173.
112. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP1, and GLP2 receptors. Recept. Channels 2002; 8: 179-188.
113. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 2003; 55: 167-194.
114. Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, De Souza EB. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. Sci. 1996; 17: 166-172.
115. Eckart K, Jahn O, Radulovic J, Radulovic M, Blank T, Stiedl O, Brauns O, Tezval H, Zeyda T, Spiess J. Pharmacology and biology of corticotropin-releasing factor (CRF) receptors. Recept. Channels 2002; 8: 163-177.
116. Gardella TJ, Wilson AK, Keutmann HT, Oberstein R, Potts JT Jr, Kronenberg M, Nussbaum Sr. Analysis of parathyroid hormone's principal receptor-binding region by site-directed mutagenesis and analog design. Endocrinology 1993; 132: 2024-2030.
117. Schipani E, Jensen GS, Pincus J, Nissenson RA, Gardella TJ, Juppner H. Constitutive activation of the cyclic adenosine 3′,5′-monophosphate signaling pathway by parathyroid hormone (PTH)/PTH-related peptide receptors mutated at the two loci for Jansen's metaphyseal chondrodysplasia. Mol. Endocrinol. 1997; 11: 851-858.
118. Turner PR, Mefford S, Bambino T, Nissenson RA. Transmembrane residues together with the amino terminus limit the response of the parathyroid hormone (PTH) 2 receptor to PTH-related peptide. J. Biol. Chem. 1998; 273: 3830-3837.
119. Di Paolo E, De Neef P, Moguilevsky N, Petry H, Bollen A, Waelbroeck M, Robberecht P. Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin. FEBS Lett. 1998; 424: 207-210.
120. Di Paolo E, Petry H, Moguilevsky N, Bollen A, De Neef P, Waelbroeck M, Robberecht P. Mutations of aromatic residues in the first transmembrane helix impair signalling by the secretin receptor. Recept. Channels 1999; 6: 309-315.
121. Di Paolo E, Vilardaga JP, Petry H, Moguilevsky N, Bollen A, Robberecht P, Waelbroeck M. Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality. Peptides 1999; 20: 1187-1193.
122. Asmann YW, Dong M, Ganguli S, Hadac EM, Miller LJ. Structural insights into the amino-terminus of the secretin receptor: I. Status of cysteine and cystine residues. Mol. Pharmacol. 2000; 58: 911-919.
123. Chan KY, Pang RT, Chow BK. Functional segregation of the highly conserved basic motifs within the third endoloop of the human secretin receptor. Endocrinology 2001; 142: 3926-3934.
124. Qi LJ, Leung AT, Xiong Y, Marx KA, Abou-Samra AB. Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. Biochemistry 1997; 36: 12 442-12 448.
125. Wille S, Sydow S, Palchaudhuri MR, Spiess J, Dautzenberg FM. Identification of amino acids in the N-terminal domain of corticotropin- releasing factor receptor 1 that are important determinants of high-affinity ligand binding. J. Neurochem. 1999; 72: 388-395.
126. Dautzenberg FM, Higelin J, Brauns O, Butscha B, Hauger RL. Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart. Mol. Pharmacol. 2002; 61: 1132-1139.
127. Unson CG, Wu CR, Merrifield RB. Roles of aspartic acid 15 and 21 in glucagon action: receptor anchor and surrogates for aspartic acid 9. Biochemistry 1994; 33: 6884-6887.
128. Unson CG, Wu CR, Fitzpatrick KJ, Merrifield RB. Multiple-site replacement analogs of glucagon. A molecular basis for antagonist design. J. Biol. Chem. 1994; 269: 12 548-12 551.
129. Unson CG, Merrifield RB. Identification of an essential serine residue in glucagon: implication for an active site triad. Proc. Natl Acad. Sci. USA 1994; 91: 454-458.
130. Carruthers CJ, Unson CG, Kim HN, Sakmar TP. Synthesis and expression of a gene for the rat glucagon receptor. Replacement of an aspartic acid in the extracellular domain prevents glucagon binding. J. Biol. Chem. 1994; 269: 29 321-29 328.
131. Unson CG, Cypess AM, Kim HN, Goldsmith PK, Carruthers CJ, Merrifield RB, Sakmar TP. Characterization of deletion and truncation mutants of the rat glucagon receptor. Seven transmembrane segments are necessary for receptor transport to the plasma membrane and glucagon binding. J. Biol. Chem. 1995; 270: 27 720-27 727.
132. Takhar S, Gyomorey S, Su RC, Mathi SK, Li X, Wheeler MB. The third cytoplasmic domain of the GLP1(7-36 amide) receptor is required for coupling to the adenylyl cyclase system. Endocrinology 1996; 137: 2175-2178.
133. Mathi SK, Chan Y, Li X, Wheeler MB. Scanning of the glucagon-like peptide-1 receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop. Mol. Endocrinol. 1997; 11: 424-432.
134. Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe M. Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding. Biochem. Biophys. Res. Commun. 1995; 211: 901-908.
135. Couvineau A, Fabre C, Gaudin P, Maoret JJ, Laburthe M. Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry 1996; 35: 1745-1752.
136. Juppner H, Schipani E, Bringhurst FR, McClure I, Keutmann HT, Potts JT Jr, Kronenberg HM, Abou-Samra AB, Segre GV, Gardella TJ. The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH(1-34). Endocrinology 1994; 134: 879-884.
137. Behar V, Nakamoto C, Greenberg Z, Bisello A, Suva LJ, Rosenblatt M, Chorev M. Histidine at position 5 is the specificity 'switch' between two parathyroid hormone receptor subtypes. Endocrinology 1996; 137: 4217-4224.
138. Turner PR, Bambino T, Nissenson RA. A putative selectivity filter in the G-protein-coupled receptors for parathyroid hormone and secretion. J. Biol. Chem. 1996; 271: 9205-9208.
139. Park CG, Ganguli SC, Pinon DI, Hadac EM, Miller LJ. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation. J. Pharmacol. Exp. Ther. 2000; 295: 682-688.
140. Vilardaga JP, De Neef P, Di Paolo E, Bollen A, Waelbroeck M, Robberecht P. Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination. Biochem. Biophys. Res. Commun. 1995; 211: 885-891.
141. Gourlet P, Vilardaga JP, De Neef P, Waelbroeck M, Vandermeers A, Robberecht P. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides 1996; 17: 825-829.
142. Gourlet P, Vilardaga JP, De Neef P, Vandermeers A, Waelbroeck M, Bollen A, Robberecht P. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor. Eur. J. Biochem. 1996; 239: 349-355.
143. Gourlet P, Vandermeers A, Vandermeers-Piret MC, De Neef P, Waelbroeck M, Robberecht P. Effect of introduction of an arginine 16 in VIP, PACAP and secretin on ligand affinity for the receptors. Biochim. Biophys. Acta 1996; 1314: 267-273.
144. Du K, Nicole P, Couvineau A, Laburthe M. Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP. Ann. N. Y. Acad. Sci. 1998; 865: 386-389.
145. Robberecht P, Di Paolo E, Moguilevsky N, Bollen A, Waelbroeck M. Sequences (103-110) and (116-120) of the rat secretin receptor are implicated in secretin and VIP recognition. Ann. N. Y. Acad. Sci. 2000; 921: 362-365.
146. Vilardaga JP, Di Paolo E, De Neef P, Waelbroeck M, Bollen A,
147. DeAlmeida VI, Mayo KE. Identification of binding domains of the growth hormone-releasing hormone receptor by analysis of mutant and chimeric receptor proteins. Mol. Endocrinol. 1998; 12: 750-765.
148. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinol. 1997; 11: 2048-2053.
149. Liaw CW, Grigoriadis DE, Lovenberg TW, De Souza EB, Maki RA. Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol. Endocrinol. 1997; 11: 980-985.
150. Perrin MH, Sutton S, Bain DL, Berggren WT, Vale WW. The first extracellular domain of corticotropin releasing factor-R1 contains major binding determinants for urocortin and astressin. Endocrinology 1998; 139: 566-570.
151. Dautzenberg FM, Kilpatrick GJ, Wille S, Hauger RL. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile. J. Neurochem. 1999; 73: 821-829.
152. Sydow S, Flaccus A, Fischer A, Spiess J. The role of the fourth extracellular domain of the rat corticotropin- releasing factor receptor type 1 in ligand binding. Eur. J. Biochem. 1999; 259: 55-62.
153. Assil IQ, Qi LJ, Arai M, Shomali M, Abou-Samra AB. Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction. Biochemistry 2001; 40: 1187-1195.
154. Gelling RW, Wheeler MB, Xue J, Gyomorey S, Nian C, Pederson RA, McIntosh CH. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor. Endocrinology 1997; 138: 2640-2643.
155. Unson CG, Wu CR, Jiang Y, Yoo B, Cheung C, Sakmar TP, Merrifield RB. Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling. Biochemistry 2002; 41: 11 795-11 803.
156. Runge S, Gram C, Brauner-Osborne H, Madsen K, Knudsen LB, Wulff BS. Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J. Biol. Chem. 2003; 278: 28 005-28 010.
157. Runge S, Wulff BS, Madsen K, Brauner-Osborne H, Knudsen LB. Different domains of the glucagon and glucagon-like peptide 1 receptors provide the critical determinants of ligand selectivity. Br. J. Pharmacol. 2003; 138: 787-794.
158. Assil-Kishawi I, Abou-Samra AB. Sauvagine cross-links to the second extracellular loop of the corticotropin-releasing factor type 1 receptor. J. Biol. Chem. 2002; 277: 32 558-32 561.
159. Fry DC, Madison VS, Bolin DR, Greeley DN, Toome V, Wegrzynski BB. Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics. Biochemistry 1989; 28: 2399-2409.
160. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, Laburthe M. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J. Biol. Chem. 2000; 275: 24 003-24 012.
161. Inooka H, Endo S, Kitada C, Mizuta E, Fujino M. Pituitary adenylate cyclase activating polypeptide (PACAP) with 27 residues. Conformation determined by 1H NMR and CD spectroscopies and distance geometry in 25% methanol solution. Int. J. Pept. Protein Res. 1992; 40: 456-464.
162. Wray V, Kakoschke C, Nokihara K, Naruse S. Solution structure of pituitary adenylate cyclase activating polypeptide by nuclear magnetic resonance spectroscopy. Biochemistry 1993; 32: 5832-5841.
163. Braun W, Wider G, Lee KH, Wuthrich K. Conformation of glucagon in a lipid-water interphase by 1H nuclear magnetic resonance. J. Mol. Biol. 1983; 169: 921-948.
164. Thornton K, Gorenstein DG. Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 1994; 33: 3532-3539.
165. Fry DC, Madison VS, Greeley DN, Felix AM, Heimer EP, Frohman L, Campbell RM, Mowles TF, Toome V, Wegrzynski BB. Solution structures of cyclic and dicyclic analogues of growth hormone releasing factor as determined by two-dimensional NMR and CD spectroscopies and constrained molecular dynamics. Biopolymers 1992; 32: 649-666.
166. Cervini LA, Donaldson CJ, Koerber SC, Vale WW, Rivier JE. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. J. Med. Chem. 1998; 41: 717-727.
167. Marx UC, Austermann S, Bayer P, Adermann K, Ejchart A, Sticht H, Walter S, Schmid FX, Jaenicke R, Forssmann WG, et al. Structure of human parathyroid hormone 1-37 in solution. J. Biol. Chem. 1995; 270: 15 194-15 202.
168. Klaus W, Dieckmann T, Wray V, Schomburg D, Wingender E, Mayer H. Investigation of the solution structure of the human parathyroid hormone fragment (1-34) by 1H NMR spectroscopy, distance geometry, and molecular dynamics calculations. Biochemistry 1991; 30: 6936-6942.
169. Strickland LA, Bozzato RP, Kronis KA. Structure of human parathyroid hormone(1-34) in the presence of solvents and micelles. Biochemistry 1993; 32: 6050-6057.
170. Weidler M, Marx UC, Seidel G, Schafer W, Hoffmann E, Esswein A, Rosch P. The structure of human parathyroid hormone-related protein(1-34) in near-physiological solution. FEBS Lett. 1999; 444: 239-244.
171. Romier C, Bernassau JM, Cambillau C, Darbon H. Solution structure of human corticotropin releasing factor by 1H NMR and distance geometry with restrained molecular dynamics. Protein Eng. 1993; 6: 149-156.
172. Ryu KS, Choi BS, Chi SW, Kim SH, Kim H. Structures of ovine corticotropin-releasing factor and its Ala32 mutant as studied by CD and NMR techniques. J. Biochem. (Tokyo) 2000; 127: 687-694.
173. Lynch B, Kaiser ET. Biological properties of two models of calcitonin gene related peptide with idealized amphiphilic alpha-helices of different lengths. Biochemistry 1988; 27: 7600-7607.
174. Motta A, Andreotti G, Amodeo P, Strazzullo G, Castiglione Morelli MA. Solution structure of human calcitonin in membrane-mimetic environment: the role of the amphipathic helix. Proteins 1998; 32: 314-323.
175. Doi M, Kobayashi Y, Kyogoku Y, Takimoto M, Goda K. Structure study of human calcitonin. In Peptides: Chemistry, Structure and Biology, Proceedings of the Eleventh American Peptide Symposium, Rivier JE, Marshall R (eds), ESCOM: Leiden, The Netherlands, 1990; 165-167.
176. Meadows RP, Nikonowicz EP, Jones CR, Bastian JW, Gorenstein DG. Two-dimensional NMR and structure determination of salmon calcitonin in methanol. Biochemistry 1991; 30: 1247-1254.
177. Meyer JP, Pelton JT, Hoflack J, Saudek V. Solution structure of salmon calcitonin. Biopolymers 1991; 31: 233-241.
178. Motta A, Pastore A, Goud NA, Castiglione Morelli MA. Solution conformation of salmon calcitonin in sodium dodecyl sulfate micelles as determined by two-dimensional NMR and distance geometry calculations. Biochemistry 1991; 30: 10 444-10 450.